Issues
-
Cover Image
Cover Image
Src inhibition blocks angiogenesis in an in vivo model. Surgical gel foam sponges were soaked in conditioned medium from L3.6pl pancreatic tumor cells, implanted subcutaneously into C3H mice, harvested 14 days later, and frozen sections were examined for CD31 indicative of mouse vessels (brown staining). Robust infiltration of vessels is induced by angiogenic factors in the culture medium (top left), but this process is almost completely inhibited when medium from cells treated with the Src inhibitor AP23846 (top right) is used. rIl8 and rVEGF directly added to the gel foam also induce angiogenesis (bottom left). This angiogenesis is not blocked when a single dose of AP23846 is added directly to the gel foam (bottom right), demonstrating that residual inhibitor in the culture medium was not responsible for decreased angiogenesis. For details, see Summy et al. in this issue.
- PDF Icon PDF LinkTable of Contents
ARTICLE
Transcriptional targeting modalities in breast cancer gene therapy using adenovirus vectors controlled by α-lactalbumin promoter
Transcript profiling in peripheral T-cell lymphoma, not otherwise specified, and diffuse large B-cell lymphoma identifies distinct tumor profile signatures
Sensitization of DNA damage–induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3σ and survivin
AP23846, a novel and highly potent Src family kinase inhibitor, reduces vascular endothelial growth factor and interleukin-8 expression in human solid tumor cell lines and abrogates downstream angiogenic processes
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.